What evidence is there for the benefit of lower target BP in CKD patients?
SPRINT is the largest trial testing 2 BP targets in CKD with approximately 2600 CKD patients. A meta-analysis by Malhotra et al., examining death as an outcome exclusively in the CKD subgroups of the large hypertension treatment RCTs, also found a benefit of lower target BP. Garrison et al. analyzed RCTs conducted in hypertensive adults aged 65 years or older and reported outcomes for higher SBP (150 160 mm Hg) or DBP (95 105 mm Hg), compared to a lower treatment target. However, there are very few major trials and relatively few events in this meta-analysis.